Viz.ai has been awarded a CE mark for its artificial intelligence (AI)-powered stroke care software, affirming its conformity with European health, safety and environmental protection standards for products sold within the European Economic Area. Viz.ai’s intelligent care coordination system connects multidisciplinary care teams earlier, coordinates care and puts patients first with the company’s software suite, which has been clinically proven to synchronise stroke care, decrease time to treatment and greatly improve patient outcomes, according to a press release.
In the European Union (EU), stroke is the second most common cause of death and a leading cause of adult disability, but only an estimated 1.9% receive a potentially lifesaving, minimally invasive endovascular procedure that removes blood clots.
Viz.ai’s flagship solution, Viz LVO, uses AI to automatically detect suspected large vessel occlusion (LVO) strokes on computed tomography angiography (CTA) imaging and directly alert on-call stroke specialists about potentially treatable patients in a standalone or multi-hospital network.
“Minutes matter when you are having a stroke, which is why Viz.ai is dedicated to reducing time to treatment and improving patient outcomes through improved care coordination,” said Chris Mansi, co-founder and CEO of Viz.ai. “The CE mark allows us to bring our leading AI software to the EU, significantly expanding the number of patients we can help get access to life-saving therapy.”
Viz.ai is the most studied stroke workflow software available today, the release adds. A recent, large, real-world multicentre study using Viz.ai found a median time-to-notification of five minutes and 45 seconds across all of the sites involved when using Viz LVO. In the study, containing the largest health AI data set to date, Viz LVO achieved 96% sensitivity and 94% specificity in identifying LVOs in 2,544 consecutive patients from 139 hospitals using scanners from multiple manufacturers. Faster triage with Viz LVO enables the identification and treatment of more patients who are eligible for thrombectomy, which improves patient outcomes and reduces the chances of long-term disability.